195 related articles for article (PubMed ID: 11122801)
1. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.
Selman AE; Copeland LJ
Curr Oncol Rep; 1999 Sep; 1(1):71-6. PubMed ID: 11122801
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
3. The value of CA 125 measurement before second-look laparotomy in patients with ovarian carcinoma.
Hørding U; Toftager-Larsen K; Lund B; Dreisler A; Daugaard S; Lundvall F; Knudsen JB; Bock JE
Eur J Gynaecol Oncol; 1994; 15(3):217-21. PubMed ID: 7957327
[TBL] [Abstract][Full Text] [Related]
4. A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant.
Frasci G; Conforti S; Zullo F; Mastrantonio P; Comella G; Comella P; Persico G; Iaffaioli RV
Cancer; 1996 Mar; 77(6):1122-30. PubMed ID: 8635133
[TBL] [Abstract][Full Text] [Related]
5. The role of second-look laparotomy in the long-term survival in ovarian cancer.
Tuxen MK; Strauss G; Lund B; Hansen M
Ann Oncol; 1997 Jul; 8(7):643-8. PubMed ID: 9296216
[TBL] [Abstract][Full Text] [Related]
6. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.
Jäger W; Adam R; Wildt L; Lang N
Arch Gynecol Obstet; 1988; 243(2):91-9. PubMed ID: 2456743
[TBL] [Abstract][Full Text] [Related]
7. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
Sevinc A; Camci C; Turk HM; Buyukberber S
Oncology; 2003; 65(1):1-6. PubMed ID: 12837976
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of tumour markers in the management of ovarian cancer.
Rustin GJ
Ann Clin Biochem; 1996 Jul; 33 ( Pt 4)():284-9. PubMed ID: 8836386
[No Abstract] [Full Text] [Related]
9. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
Meden H; Rath W; Teichmann A; Kuhn W
Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer.
Sugiyama T; Nishida T; Komai K; Nishimura H; Yakushiji M; Nishimura H
Int J Gynaecol Obstet; 1996 Sep; 54(3):251-6. PubMed ID: 8889633
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.
Odunsi K; Ghamande S; Chandrasekaran EV; Ta A; Moysich KB; Driscoll D; Matta K; Lele S
Am J Obstet Gynecol; 2002 Sep; 187(3):575-80. PubMed ID: 12237630
[TBL] [Abstract][Full Text] [Related]
12. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the second-look laparotomy in the management of carcinoma of the ovary.
Yakushiji M; Kato T
Semin Surg Oncol; 1986; 2(2):72-5. PubMed ID: 3454039
[TBL] [Abstract][Full Text] [Related]
14. Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy?
Byrom J; Widjaja E; Redman CW; Jones PW; Tebby S
BJOG; 2002 Apr; 109(4):369-75. PubMed ID: 12013156
[TBL] [Abstract][Full Text] [Related]
15. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure.
Folk JJ; Botsford M; Musa AG
Gynecol Oncol; 1995 May; 57(2):178-82. PubMed ID: 7729730
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
García Enguídanos A; Crespo Azanza E; Díaz Recaséns J; Lobo Samper F; Jorge Herrero JA; Sáinz de la Cuesta Abbad R
Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland.
Markowska J; Wilkoszarska J; Emerich J; Debniak J; Popiela A; Pańszczak M; Kornafel J; Rossochacka B; Fisher Z; Goluda M; Małecki P
Eur J Gynaecol Oncol; 2000; 21(2):164-7. PubMed ID: 10843477
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma.
Lund B; Williamson P
Obstet Gynecol; 1990 Oct; 76(4):617-22. PubMed ID: 2216190
[TBL] [Abstract][Full Text] [Related]
20. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year.
Low RN; Duggan B; Barone RM; Saleh F; Song SY
Radiology; 2005 Jun; 235(3):918-26. PubMed ID: 15914479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
